[1]Arredondo M, Núez MT. Iron and copper metabolism[J]. Mol Aspects Med, 2005, 26(4-5): 313-327.
[2]Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018[J]. Cell Death Differ, 2018, 25(3): 486-541.
[3]Tang D, Kang R, Berghe TV, et al. The molecular machinery of regulated cell death[J]. Cell Res, 2019, 29(5): 347-364.
[4]Santagostino SF, Assenmacher CA, Tarrant JC,et al. Mechanisms of regulated cell death: Current perspectives[J]. Vet Pathol, 2021, 58(4): 596-623.
[5]Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins[J]. Science, 2022, 375(6586): 1254-1261.
[6]Maher P. Potentiation of glutathione loss and nerve cell death by the transition metals iron and copper:Implications for agerelated neurodegenerative diseases[J]. Free Radic Biol Med, 2018, 115: 92-104.
[7]Bandmann O, Weiss KH, Kaler SG. Wilson′s disease and other neurological copper disorders[J].Lancet Neurol, 2015, 14(1): 103-113.
[8]Niu YY, Zhang YY, Zhu Z, et al. Elevated intracellular copper contributes a unique role to kidney fibrosis by lysyl oxidase mediated matrix crosslinking[J]. Cell Death Dis, 2020, 11(3): 211.
[9]RostkowskaNadolska B, Po'sspiech L, Bochnia M. Content of trace elements in serum of patients with carcinoma of the larynx[J]. Arch Immunol Ther Exp (Warsz), 1999, 47(5): 321-325.
[10]Kuo HW, Chen SF, Wu CC, et al. Serum and tissue trace elements in patients with breast cancer in Taiwan[J]. Biol Trace Elem Res, 2002, 89(1): 1-11.
[11] Garber K. Cancer′s copper connections[J]. Science, 2015, 349(6244): 129.
[12]CarreiraBarral I, RiopedreFernández M, de Blas A, et al. Ditopic binuclear copper(Ⅱ) complexes for DNA cleavage[J]. J Inorg Biochem, 2020, 205: 110995.
[13]Food and Drug Administration, HHS. Food labeling: revision of the nutrition and supplement facts labels. Final rule[J]. Fed Regist, 2016, 81(103): 33741-33999.
[14]Nose Y, Wood LK, Kim BE, et al. Ctr1 is an apical copper transporter in mammalian intestinal epithelial cells in vivo that is controlled at the level of protein stability[J]. J Biol Chem, 2010, 285(42): 32385-32392.
[15]Festa RA, Thiele DJ. Copper: an essential metal in biology[J]. Curr Biol, 2011, 21(21): R877-R883.
[16]Cox DW, Moore SD. Copper transporting Ptype ATPases and human disease[J]. J Bioenerg Biomembr, 2002, 34(5): 333-338.
[17]Chen J, Jiang Y, Shi H, et al. The molecular mechanisms of copper metabolism and its roles in human diseases[J]. Pflugers Arch, 2020, 472(10): 1415-1429.
[18]Osawa S, Kitanishi K, Kiuchi M, et al. Accelerated redox reaction of hydrogen peroxide by employing locally concentrated state of copper catalysts on polymer chain[J]. Macromol Rapid Commun, 2021, 42(16): e2100274.
[19]Halliwell B, Chirico S. Lipid peroxidation: its mechanism, measurement, and significance[J]. Am J Clin Nutr, 1993, 57(5 Suppl): 715S-725S.
[20]Anandhan A, RodriguezRocha H, Bohovych I, et al. Overexpression of alphasynuclein at nontoxic levels increases dopaminergic cell death induced bycopper exposure via modulation of protein degradation pathways[J]. Neurobiol Dis, 2015, 81: 76-92.
[21]Klaunig JE. Oxidative stress and cancer[J]. Curr Pharm Des, 2018, 24(40): 4771-4778.
[22]Gupte A, Mumper RJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment[J]. Cancer Treat Rev, 2009, 35(1): 32-46.
[23]Aust SD, Morehouse LA, Thomas CE. Role of metals in oxygen radical reactions[J]. J Free Radic Biol Med, 1985, 1(1): 3-25.
[24]DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism[J]. Sci Adv, 2016, 2(5): e1600200.
[25]MartínezReyes I, Chandel NS. Cancer metabolism: looking forward[J]. Nat Rev Cancer, 2021, 21(10): 669-680.
[26]Denoyer D, Masaldan S, La Fontaine S, et al. Targeting copper in cancer therapy: ′Copper That Cancer′[J]. Metallomics, 2015, 7(11): 1459-1476.
[27]Shimada K, Reznik E, Stokes ME, et al. Copperbinding small molecule induces oxidative stress and cellcycle arrest in glioblastomapatientderived cells[J]. Cell Chem Biol, 2018, 25(5): 585-594.e7.
[28]Yip NC, Fombon IS, Liu P, et al. Disulfiram modulated ROSMAPK and NFκB pathways and targeted breast cancer cells with cancer stem celllike properties[J]. Br J Cancer, 2011, 104(10): 1564-1574.
[29]Cen D, Brayton D, Shahandeh B, et al. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells[J]. J Med Chem, 2004, 47(27): 6914-6920.
[30]Narayanan S, Cai CY, Assaraf YG, et al. Targeting the ubiquitinproteasome pathway to overcome anticancer drug resistance[J]. Drug Resist Updat, 2020, 48: 100663.
[31]Cengiz Seval G, Beksac M. The safety of bortezomib for the treatment of multiple myeloma[J]. Expert Opin Drug Saf, 2018, 17(9): 953-962.
[32]Chen D, Cui QC, Yang H, et al. Disulfiram, a clinically used antialcoholism drug and copperbinding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity[J]. Cancer Res, 2006, 66(21): 10425-10433.
[33]Skrott Z, Mistrik M, Andersen KK, et al. Alcoholabuse drug disulfiram targets cancer via p97 segregase adaptor NPL4[J]. Nature, 2017, 552(7684): 194-199.
[34]Tsvetkov P, Detappe A, Cai K, et al. Mitochondrial metabolism promotes adaptation to proteotoxic stress[J]. Nat Chem Biol, 2019, 15(7): 681-689.
[35]胡善林,莫钦国,罗建芳,等.铁死亡在肿瘤中的研究进展[J]. 江苏大学学报(医学版), 2020, 30(2): 116-120.
[36]Rowland EA, Snowden CK, Cristea IM. Protein lipoylation: an evolutionarily conserved metabolic regulator of health and disease[J]. Curr Opin Chem Biol, 2018, 42: 76-85.
[37]Tang Q, Guo Y, Meng L, et al. Chemical tagging of protein lipoylation[J]. Angew Chem Int Ed Engl, 2021, 60(8): 4028-4033.
[38]da Silva DA, De Luca A, Squitti R, et al. Copper in tumors and the use of copperbased compounds in cancer treatment[J]. J Inorg Biochem, 2022, 226: 111634.
[39]Ge EJ, Bush AI, Casini A, et al. Connecting copper and cancer: from transition metal signalling to metalloplasia[J]. Nat Rev Cancer, 2022, 22(2): 102-113.
[40]Shanbhag VC, Gudekar N, Jasmer K, et al. Copper metabolism as a unique vulnerability in cancer[J]. Biochim Biophys Acta Mol Cell Res, 2021, 1868(2): 118893.
[41]Tang Z, Liu Y, He M, et al. Chemodynamic therapy: Tumour microenvironmentmediated Fenton and Fentonlike reactions[J]. Angew Chem Int Ed Engl, 2019, 58(4): 946-956.
[42]Kordestani N, Rudbari HA, Fernandes AR, et al. Antiproliferative activities of diiminebased mixed ligand copper(Ⅱ) complexes[J]. ACS Comb Sci, 2020, 22(2): 89-99.
[43]Luo B, Chen L, Hong Z, et al. A simple and feasible atomprecise biotinylated Cu(Ⅰ) complex for tumortargeted chemodynamic therapy[J]. Chem Commun (Camb), 2021, 57(49): 6046-6049.
[44]Zheng R, Cheng Y, Qi F, et al. Biodegradable copperbased nanoparticles augmented chemodynamic therapy through deep penetration and suppressing antioxidant activity in tumors[J]. Adv Healthc Mater, 2021, 10(14): e2100412.
[45]Chen Q, Zheng Z, He X, et al. A tumortargeted theranostic nanomedicine with strong absorption in the NIRⅡ biowindow for imageguided multigradient therapy[J]. J Mater Chem B, 2020, 8(41): 9492-9501.
[46]Liu C, Chen Y, Zhao J, et al. Selfassembly of copperDNAzyme nanohybrids for dualcatalytic tumor therapy[J]. Angew Chem Int Ed Engl, 2021, 60(26): 14324-14328.
[47]Liu J, Shi J, Nie W, et al. Recent progress in the development of multifunctional nanoplatform for precise tumor phototherapy[J]. Adv Healthc Mater, 2021, 10(1): e2001207.
[48]Kwiatkowski S, Knap B, Przystupski D, et al. Photodynamic therapymechanisms, photosensitizers and combinations[J]. Biomed Pharmacother, 2018, 106: 1098-1107.
[49]Wang J, Xu M, Wang D, et al. Copperdoped carbon dots for optical bioimaging and photodynamic therapy[J]. Inorg Chem, 2019, 58(19): 13394-13402.
[50]Shrestha S, Wu J, Sah B, et al. Xray induced photodynamic therapy with coppercysteamine nanoparticles in mice tumors[J]. Proc Natl Acad Sci U S A, 2019, 116(34): 16823-16828.
[51]Weng Y, Guan S, Wang L, et al. Defective porous carbon polyhedra decorated with copper nanoparticles for enhanced NIRdriven photothermal cancer therapy[J]. Small, 2020, 16(1): e1905184.
[52]Hou L, Shan X, Hao L, et al. Copper sulfide nanoparticlebased localized drug delivery system as an effective cancer synergistic treatment and theranostic platform[J]. Acta Biomater, 2017, 54: 307-320.
[53]Bortolozzi R, Viola G, Porcù E, et al. A novel copper(Ⅰ) complex induces ERstressmediated apoptosis and sensitizes Bacute lymphoblastic leukemia cells to chemotherapeutic agents[J]. Oncotarget, 2014, 5(15): 5978-5991.
[54]Li Y. Copper homeostasis: Emergingtarget for cancer treatment[J]. IUBMB Life, 2020, 72(9): 1900-1908.
[55]Cui H, Zhang AJ, McKeage MJ, et al. Copper transporter 1 in human colorectal cancer cell lines: Effects of endogenous and modified expression on oxaliplatin cytotoxicity[J]. J Inorg Biochem, 2017, 177: 249-258.
[56]Ishida S, McCormick F, SmithMcCune K, et al. Enhancing tumorspecific uptake of the anticancer drug cisplatin with a copper chelator[J]. Cancer Cell, 2010, 17(6): 574-583.
[57]Li YQ, Yin JY, Liu ZQ, et al. Copper efflux transporters ATP7A and ATP7B: Novel biomarkers for platinum drug resistance and targets for therapy[J]. IUBMB Life, 2018, 70(3): 183-191.
[58]Zhu X, Lang J. Soluble PD1 and PDL1: predictive and prognostic significance in cancer[J]. Oncotarget, 2017, 8(57): 97671-97682.
[59]Voli F, Valli E, Lerra L, et al. Intratumoral copper modulates PDL1 expression and influences tumor immune evasion[J]. Cancer Res, 2020, 80(19): 4129-4144.
[60]Goodman VL, Brewer GJ, Merajver SD. Control of copper status for cancer therapy[J]. Curr Cancer Drug Targets, 2005, 5(7): 543-549.
|